Results 161 to 170 of about 3,791 (213)

False-positive [68Ga]Ga-FAPI-04 PET/CT Following Treatment of 177Lu-DOTATATE PRRT in a Patient With Metastatic High-grade Well-differentiated Neuroendocrine Tumor.

Clinical Nuclear Medicine
We present a high-grade well-differentiated NET with large lesions that demonstrated both SSTR and [18F]F-FDG avidity on baseline PET/CT, an outstanding response following 177Lu-DOTATATE-PRRT with complete resolution of SSTR and [18F]F-FDG uptake, and ...
R. Parghane, Subhash Yadav, Austin Saju, Sandip Basu   +3 more
semanticscholar   +1 more source

¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine, 2017
_To the Editor:_ Although the results of the multicenter, randomized, controlled Neuroendocrine Tumors Therapy (NETTER-1) trial reported by Strosberg et al. (Jan. 12 issue) validate the experience gained over the past decade by many institutions, we think that they overstate the toxic effects of lutetium-177 (177Lu)–Dotatate and potentially ...
Michael S, Hofman, Michael, Michael, Rodney J, Hicks   +2 more
openaire   +5 more sources

A False-Negative 123I-MIBG SPECT/CT With True-Positive 68Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177Lu-DOTATATE Therapy.

Clinical Nuclear Medicine
A 10-year-old girl with high-risk neuroblastoma underwent 123I-MIBG SPECT/CT and 68Ga-DOTATE PET/CT, which both showed multiple bone metastases. However, following 177Lu-DOTATATE therapy, only 68Ga-DOTATATE PET/CT identified residual lesions with ...
Siqi Li, Yanfeng Xu, Xia Lu, Wei Wang, Jigang Yang   +4 more
semanticscholar   +1 more source

Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy

Annals of Nuclear Medicine, 2018
As radionuclide therapy is gaining importance in palliative treatment of patients suffering from neuroendocrine tumour (NET) as well as castration resistant prostate cancer (CRPC), the radiation protection of patients, staff, family members and the general public is of increasing interest.
Christian, Mair, Boris, Warwitz, Katharina, Fink, Lorenza, Scarpa, Bernhard, Nilica, Johanna, Maffey-Steffan, Sabine, Buxbaum, Irene J, Virgolini   +7 more
openaire   +2 more sources

177Lu-DOTATATE Tedavi Sonucunu Öngören Faktörlerin Belirlenmesi

2023
Amaç: 177Lu-DOTATATE tedavisi alan hastalarda tedaviye sonucunu öngörenfaktörlerin belirleyerek tedaviden fayda görmesi beklenen hastalarınseçiminde bu faktörlerden yararlanılmasını sağlamaktır.Yöntem:  Merkezimizde 2015-2023 yılları arasında 177Lu-DOTATATEtedavisi uygulanan hastalar retrospektif olarak değerlendirildi.
Karahan Şen, Nazlı Pınar, Bozdemir, Tolga Can, Arslan, Tahmına, Çapa Kaya, Gamze   +3 more
openaire   +1 more source

Medullary Thyroid Carcinoma (MTC) Treated With 177Lu-DOTATATE PRRT

Clinical Nuclear Medicine, 2015
Two patients diagnosed with metastatic medullary thyroid carcinoma (MTC) were referred for peptide receptor radionuclide therapy (PRRT) with Lu-[DOTA,Tyr]octreotate (DOTATATE). Each patient was treated with 4 doses of Lu-DOTATATE given 2 months apart. One patient achieved stable disease for 10 months then chose to pursue surgery, and the other achieved
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

[Indications and Practice of a New Radionuclide Therapy, 177Lu-DOTATATE in Japan].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Peptide receptor radionuclide therapy(PRRT)is a pioneer drug in the rapid development of radio-theranostics, and a paradigm-shifting approach to treat neuroendocrine tumor( NET). The NETTER-1 trial for NETs of the midgut is currently the only global phase Ⅲ prospective clinical trial demonstrating the efficacy and safety of PRRT.
Shoko, Takano, Noritoshi, Kobayashi, Yasushi, Ichikawa, Masaharu, Hata   +3 more
openaire   +1 more source

177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer

Clinical Nuclear Medicine, 2018
Introduction Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by 68Ga/177Lu-DOTATATE could evolve as a novel theranostic option.
Wolfgang, Roll, Burkhard, Riemann, Michael, Schäfers, Lars, Stegger, Alexis, Vrachimis   +4 more
openaire   +2 more sources

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE.

PET clinics, 2023
177Lu-DOTA-TATE therapy is a highly effective therapy in metastatic, well-differentiated, somatostatin receptor-positive GEP-neuroendocrine tumors (NETs) with mostly tolerable adverse effects. Guidelines generally refer to peptide receptor radionuclide therapy as a second-line therapy after SSA in gastroenteric and second- or third-line therapy in ...
Yasemin, Sanli, Dilara, Denizmen, Rathan M, Subramaniam   +2 more
openaire   +1 more source

Post-marketing Safety Evaluation of Lutathera (177Lu-DOTATATE): A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.

Clinical Nuclear Medicine
BACKGROUND Lutathera, a key therapy for gastroenteropancreatic neuroendocrine tumors, has demonstrated efficacy, but its real-world safety profile remains unclear. This study aims to conduct a comprehensive analysis of the adverse events (AEs) associated
Heng Chen, Junlong Ma
semanticscholar   +1 more source